| Literature DB >> 32787285 |
Raleigh M Linville1,2, Jackson G DeStefano1,3, Renée F Nerenberg1,2, Gabrielle N Grifno1,2, Robert Ye1, Erin Gallagher1,3, Peter C Searson1,2,3.
Abstract
Brain microvascular endothelial cells derived from induced pluripotent stem cells (dhBMECs) are a scalable and reproducible resource for studies of the human blood-brain barrier, including mechanisms and strategies for drug delivery. Confluent monolayers of dhBMECs recapitulate key in vivo functions including tight junctions to limit paracellular permeability and efflux and nutrient transport to regulate transcellular permeability. Techniques for cryopreservation of dhBMECs have been reported; however, functional validation studies after long-term cryopreservation have not been extensively performed. Here, we characterize dhBMECs after 1 year of cryopreservation using selective purification on extracellular matrix-treated surfaces and ROCK inhibition. One-year cryopreserved dhBMECs maintain functionality of tight junctions, efflux pumps, and nutrient transporters with stable protein localization and gene expression. Cryopreservation is associated with a decrease in the yield of adherent cells and unique responses to cell stress, resulting in altered paracellular permeability of Lucifer yellow. Additionally, cryopreserved dhBMECs reliably form functional three-dimensional microvessels independent of cryopreservation length, with permeabilities lower than non-cryopreserved two-dimensional models. Long-term cryopreservation of dhBMECs offers key advantages including increased scalability, reduced batch-to-batch effects, the ability to conduct well-controlled follow up studies, and support of multisite collaboration from the same cell stock, all while maintaining phenotype for screening pharmaceutical agents.Entities:
Keywords: blood−brain barrier; brain microvascular endothelial cells; cryopreservation; in vitro modeling; permeability; three-dimensional models
Mesh:
Year: 2020 PMID: 32787285 DOI: 10.1021/acs.molpharmaceut.0c00484
Source DB: PubMed Journal: Mol Pharm ISSN: 1543-8384 Impact factor: 4.939